Full-Time

Senior Director

Cardiology Platform Architecture & Interoperability

Posted on 7/4/2026

Philips

Philips

Manufactures sleep therapy and respiratory devices

Compensation Overview

$212k - $360k/yr

+ Annual incentive bonus + Sales commission + Long-term incentives

Cambridge, MA, USA + 1 more

More locations: Malvern, PA, USA

Hybrid

At least three days per week in the office; the role is based in Cambridge, MA or Malvern, PA.

Bachelor's, Master's

Category
Software Engineering
Required Skills
Epic (EHR)
Data Engineering
Requirements
  • A Bachelor's degree in Electrical Engineering, Electronic Engineering, Mechanical Engineering, Computer Science Engineering, Innovation, Business, or an equivalent field, or a Master's degree in one of these fields.
  • At least 11 years of experience with a Bachelor's degree or at least 9 years of experience with a Master's degree in manufacturing, production, engineering, management, system design, research and development, or an equivalent area.
  • Experience defining and scaling enterprise healthcare platforms or informatics systems.
  • Ability to successfully perform the stated minimum physical, cognitive, and environmental job requirements with or without accommodation.
Responsibilities
  • Own the target architecture for a unified cardiology and patient monitoring platform within AM&D.
  • Establish platform principles covering interoperability, data models, device integration, and platform services.
  • Lead the strategy and execution of healthcare interoperability, including EMR integration, HL7, FHIR, SMART, and SMART on FHIR.
  • Drive adoption of IHE frameworks, DICOM, and enterprise integration patterns.
  • Define platform deployment models across cloud-native, hybrid, and on-premise hospital environments.
  • Establish architectural patterns for multi-tenant SaaS, data pipelines, real-world evidence, and secure, compliant systems.
  • Partner with R&D to align work with platform architecture while avoiding constraints from legacy systems.
  • Collaborate with HPM to identify shared platform opportunities, reuse potential, and aligned interoperability approaches.
  • Define build, buy, and partner strategies for key platform components, including cloud, interoperability, and AI capabilities.
  • Engage with EMR ecosystem leaders, including Epic Systems and Oracle Cerner, to shape integration strategies and partnerships.
  • Act as a senior technical leader influencing Product, R&D, Clinical, and Commercial stakeholders across a matrixed organization.
  • Translate complex technical concepts into clear business decisions and executive-level communication.
Desired Qualifications
  • Experience with cardiology workflows, cardiac monitoring, or diagnostic data platforms.
  • Experience bridging ambulatory and hospital-based care environments.
  • Familiarity with AI-enabled healthcare platforms and data ecosystems.
  • Prior experience at organizations such as GE, Philips, or similar healthcare technology leaders.
  • Experience defining platform strategies across hardware, software, and data systems.
  • Deep expertise in EMR integration and interoperability, including HL7, FHIR, SMART, and SMART on FHIR.
  • Strong understanding of healthcare interoperability frameworks, including IHE and DICOM.
  • Experience with cloud-native, hybrid, and on-premise healthcare deployments.
  • Ability to influence large, complex, matrixed organizations without direct authority.
  • Strong executive communication skills and ability to translate technical depth into business impact.

Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.

Company Size

N/A

Company Stage

Acquired

Total Funding

$164.7M

Headquarters

Murrysville, Pennsylvania

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • More than 99% of registered CPAP and BiPAP recalls were remediated globally by December 2025.
  • Philips reported Q1 2026 connected care growth and reiterated full-year guidance in May.
  • Respironics-related charges fell to EUR 209 million in 2025 after major settlements finalized.

What critics are saying

  • FDA consent decree still bars new U.S. CPAP and BiPAP sales in 2026.
  • Repeated FDA noncompliance can keep Philips Respironics locked out of the U.S. market indefinitely.
  • The 2021 recall remains active; ventilator remediation and lawsuits keep liability and scrutiny alive.

What makes Philips unique

  • Philips Respironics services recalled U.S. devices and sells parts under the 2024 consent decree.
  • Outside the U.S., Philips Respironics still sells sleep and respiratory devices in 2026.
  • Its 15-million-device installed base gives it unmatched service reach and replacement leverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.

INACTIVE